Silo Pharma Inc. (NASDAQ: SILO) has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent application covering its lead intranasal therapeutic, SPC-15, aimed at treating post-traumatic stress disorder (PTSD). The patent, titled “Compositions and Methods for the Prevention of Stress-Induced Fear, Depressive-Like and Anxiety-Like Behavior,” includes both composition and method claims for the company’s proprietary approach to preventing or delaying stress-induced behavioral responses. This allowance marks a significant milestone in Silo’s efforts to advance SPC-15 through development and eventual commercialization.
A Notice of Allowance indicates that the USPTO has completed its examination and determined that the application meets the requirements for patentability. The patent will be granted shortly, providing Silo with exclusive rights to the technology in the United States. This adds to the company’s growing intellectual property portfolio, which already includes a corresponding patent issued by the Japan Patent Office earlier this year. The U.S. patent protection is a critical component of Silo’s strategy as it continues to develop SPC-15 for PTSD, a condition that affects millions of people worldwide and has limited treatment options.
The importance of this patent allowance extends beyond mere legal protection. It underscores the novelty and potential of SPC-15 in addressing stress-induced psychiatric disorders. PTSD is a debilitating condition that can arise after exposure to traumatic events, and current treatments often have limitations in efficacy and side effects. SPC-15’s intranasal delivery offers a potentially rapid and non-invasive method of administration, which could improve patient compliance and outcomes. By securing patent rights, Silo is positioned to attract potential partners or investors who may be interested in advancing this therapeutic candidate.
Moreover, this development highlights Silo’s commitment to addressing underserved medical needs. The company’s therapeutic focus includes stress-induced psychiatric disorders, chronic pain, and central nervous system diseases. Alongside SPC-15, Silo’s portfolio features SP-26 for fibromyalgia and chronic pain, as well as preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Research is conducted in collaboration with leading universities and laboratories, which may accelerate the translation of these programs into clinical trials.
For investors, the patent allowance may signal progress in Silo’s pipeline and reinforce the company’s potential for long-term value creation. Intellectual property is a key driver in the biopharmaceutical industry, and a strong patent estate can provide a competitive edge. The U.S. patent for SPC-15 not only protects the company’s innovation but also facilitates potential licensing opportunities or collaborations that could bring the therapy to market faster.
To view the full press release, visit https://ibn.fm/Hh4Z6. For the latest news and updates relating to SILO, visit the company’s newsroom at https://ibn.fm/SILO.
